$BCRX News Article - BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months | Benzinga
https://marketwirenews.com/news-releases/bioc...95432.html